{
  "success": true,
  "pagesUsed": [
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28
  ],
  "modelUsed": "gemini-3-flash-preview",
  "eligibility": {
    "eligibilityCriterionItems": [
      {
        "id": "eci_1",
        "name": "Informed Consent",
        "text": "Signed Informed Consent Form",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_2",
        "name": "Age Requirement",
        "text": "Women or men aged ≥18 years",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_3",
        "name": "TNBC Diagnosis",
        "text": "Patients with locally advanced or metastatic, histologically documented TNBC (absence of human epidermal growth factor 2 [HER2], oestrogen receptor [ER], and progesterone receptor [PR] expression), not amenable to surgical therapy. a. HER2 negativity is defined as either of the following: IHC 0, IHC 1+ or IHC2+/in situ hybridisation (ISH)- as per American Society of Clinical Oncology (ASCO)- College of American Pathologists Guideline (CAP) guideline (ISH- is defined as a ratio of HER2 to CEP17 <2.0) (Wolff et al. 2018). b. ER and PR negativity are defined as <1% of cells expressing hormonal receptors via IHC analysis as per ASCO-CAP guideline (Hammond et al. 2010).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_4",
        "name": "Taxane Eligibility",
        "text": "Eligible for taxane monotherapy.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_5",
        "name": "Prior Therapy Status",
        "text": "No prior chemotherapy or targeted systemic therapy (including endocrine therapy) for inoperable locally advanced or metastatic TNBC. Prior radiation therapy for metastatic disease is permitted. There is no required minimum washout period for radiation therapy; however, patients should have recovered from the effects of radiation before randomisation. Previous chemotherapy for early breast cancer (eBC; neoadjuvant or adjuvant setting) is permitted if completed ≥12 months before randomisation. China Population only: Chinese traditional medicines with an approved indication for cancer treatment are permitted as long as the last administration occurred at least 2 weeks prior to randomisation.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_6",
        "name": "Tumor Tissue Availability",
        "text": "Availability of formalin-fixed paraffin-embedded (FFPE) tumour block (preferred) or at least 17 unstained slides, collected ≤3 months prior to randomisation, with an associated pathology report, if available. If a tumour sample taken within 3 months before randomisation is not available, and a tumour biopsy is not clinically feasible, the primary surgical resection sample or the most recent FFPE tumour biopsy sample may be used. Of these additional options, the most recent sample should be used. a. The tumour tissue should be of good quality based on total and viable tumour content and must be evaluated centrally for PD-L1 expression prior to enrolment. Patients whose tumour tissue is not evaluable for prospective central testing are not eligible. b. If multiple tumour specimens are submitted, patients may be eligible if at least one specimen is evaluable for PD-L1 testing, and the score measured in the most recent sample prior to enrolment will be used as the PD-L1 score for patient stratification. i. Acceptable samples include core needle biopsies for deep tumour tissue (more than one core if clinically feasible) or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions. ii. Fine needle aspiration, brushing, cell pellet from pleural effusion, bone metastases, and lavage samples are not acceptable. iii. Tumour tissue from bone metastases is not evaluable for PD-L1 expression and is therefore not acceptable.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_7",
        "name": "ECOG Performance Status",
        "text": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_8",
        "name": "Life Expectancy",
        "text": "Life expectancy ≥ 12 weeks",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_9",
        "name": "Measurable Disease",
        "text": "Measurable disease, as defined by RECIST v1.1. (Note: Previously irradiated lesions can be considered as measurable disease only if disease progression has been unequivocally documented at that site since radiation.)",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_10",
        "name": "Organ Function",
        "text": "Adequate haematologic and end-organ function, defined by the following laboratory results obtained within 2 weeks prior to the first study treatment (Cycle 1, Day 1): a. Absolute neutrophil count (ANC) ≥ 1500 cells/μL (without granulocyte colony stimulating factor [G-CSF] support within 2 weeks prior to Cycle 1, Day 1) b. Lymphocyte count ≥ 500/μL c. Platelet count ≥ 100,000/μL (without transfusion within 2 weeks prior to Cycle 1, Day 1) d. Haemoglobin ≥ 9.0 g/dL Patients may be transfused or receive erythropoietic treatment to meet this criterion. e. Aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase ≤ 2.5× the upper limit of normal (ULN), with the following exceptions: i. Patients with documented liver metastases: AST and ALT ≤ 5× ULN ii. Patients with documented liver or bone metastases: alkaline phosphatase ≤ 5× ULN f. Serum bilirubin ≤ 1.25× ULN Patients with known Gilbert’s disease who have serum bilirubin level ≤ 3× ULN may be enrolled. g. International Normalized Ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5× ULN This applies only to patients who are not receiving an anticoagulant medicinal product; patients receiving an anticoagulant medicinal product should be on a stable dose and have an INR which is not above the target therapeutic range. h. Calculated creatinine clearance (CrCl) ≥30 mL/min (Cockcroft-Gault).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_11",
        "name": "HIV Status",
        "text": "Negative human immunodeficiency virus (HIV) test at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_12",
        "name": "Hepatitis B Status (HBsAg)",
        "text": "Negative hepatitis B surface antigen (HBsAg) test at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_13",
        "name": "Hepatitis B Status (HBcAb)",
        "text": "Negative total hepatitis B core antibody (HBcAb) test at screening, or positive HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening. The HBV DNA test will be performed only for patients who have a positive HBcAb test.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_14",
        "name": "Hepatitis C Status",
        "text": "Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening. The HCV RNA test will be performed only for patients who have a positive HCV antibody test.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_15",
        "name": "Contraception (Women)",
        "text": "Women of child bearing potential must agree to either use a contraceptive method with a failure rate of ≤1% per year or to remain abstinent (refrain from heterosexual intercourse) during the treatment period and for at least 5 months after the last dose of atezolizumab/placebo, or for at least 6 months after the last dose of paclitaxel.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_16",
        "name": "Pregnancy Test",
        "text": "Women of child bearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study drug.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_17",
        "name": "Contraception (Men)",
        "text": "For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: a. With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of paclitaxel. Men must refrain from donating sperm during this same period. b. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_18",
        "name": "Spinal Cord Compression",
        "text": "Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for at least 2 weeks prior to randomisation",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_19",
        "name": "CNS Disease",
        "text": "Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases, provided all of the following criteria are met: a. Measurable disease outside the CNS b. Metastases are limited solely to cerebellar and supratentorial lesions (i.e., no metastases to midbrain, pons, medulla, or spinal cord) c. No ongoing requirement for corticosteroids as therapy for CNS disease (anticonvulsants at a stable dose are allowed) d. No stereotactic radiation within 7 days or whole-brain radiation within 14 days prior to randomisation e. No evidence of progression or haemorrhage after completion of CNS directed therapy Note: Patients with new asymptomatic CNS metastases detected at the screening scan must receive radiation therapy and/or surgery for CNS metastases. Following treatment, these patients may then be eligible if all other criteria above are met.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_20",
        "name": "Leptomeningeal Disease",
        "text": "Leptomeningeal disease",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_21",
        "name": "Effusions or Ascites",
        "text": "Uncontrolled pleural effusion, pericardial effusion, or ascites (Note: patients with indwelling catheters, such as PleurX® are allowed)",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_22",
        "name": "Tumor-related Pain",
        "text": "Uncontrolled tumour-related pain a. Patients requiring narcotic pain medication must be on a stable regimen at study entry. b. Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomisation. Patients should be recovered from the effects of radiation. There is no required minimum recovery period. c. Asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epidural metastasis that is not presently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to randomisation.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_23",
        "name": "Hypercalcemia",
        "text": "Uncontrolled hypercalcemia (>1.5 mmol/L [>6 mg/dL] ionized calcium or serum calcium [uncorrected for albumin] >3 mmol/L [>12 mg/dL] or corrected serum calcium > ULN) or clinically significant (symptomatic) hypercalcemia. Patients who are receiving bisphosphonate therapy specifically to prevent skeletal events and who do not have a history of clinically significant (symptomatic) hypercalcemia are eligible.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_24",
        "name": "Other Malignancies",
        "text": "Malignancies other than TNBC within 5 years prior to randomisation, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_25",
        "name": "Pregnancy/Lactation",
        "text": "Pregnant or lactating women, or intending to become pregnant during the study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_26",
        "name": "Uncontrolled Concomitant Disease",
        "text": "Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_27",
        "name": "Cardiovascular Disease",
        "text": "Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), myocardial infarction within 3 months prior to randomisation, unstable arrhythmias, or unstable angina. a. Patients with a known left ventricular ejection fraction (LVEF) < 40% will be excluded. b. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF < 50% must be on a stable medical regimen that is optimised in the opinion of the treating physician, in consultation with a cardiologist if appropriate.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_28",
        "name": "Abnormal ECG",
        "text": "Presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator’s opinion, including complete left bundle branch block, second- or third- degree heart block, evidence of prior myocardial infarction, or QT interval corrected using Fridericia’s formula (QTcF) > 470 ms demonstrated by at least two consecutive ECGs.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_29",
        "name": "Serious Infection",
        "text": "Serious infection requiring antibiotics within 2 weeks prior to randomisation, including but not limited to infections requiring hospitalisation or IV antibiotics, such as bacteraemia, or severe pneumonia.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_30",
        "name": "Major Surgery",
        "text": "Major surgical procedure within 4 weeks prior to randomisation or anticipation of the need for a major surgical procedure during the course of the study other than for diagnosis. Note: Placement of central venous access catheter(s) (e.g., port or similar) is not considered a major surgical procedure and is therefore permitted.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_31",
        "name": "Investigational Therapy",
        "text": "Treatment with investigational therapy within 30 days prior to initiation of study treatment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_32",
        "name": "Language/PRO Inability",
        "text": "Inability to understand the local language(s) for which the Patient Reported Outcome (PRO) questionnaires are available.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_33",
        "name": "Antibody Hypersensitivity",
        "text": "History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanised antibodies or fusion proteins.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_34",
        "name": "CHO Cell Hypersensitivity",
        "text": "Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary (CHO) cells or any component of the atezolizumab formulation.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_35",
        "name": "Autoimmune Disease",
        "text": "History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Guillain-Barré syndrome, multiple sclerosis (MS), vasculitis, or glomerulonephritis. (Note: Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study.)",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_36",
        "name": "Transplantation History",
        "text": "Prior allogeneic stem cell or solid organ transplantation",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_37",
        "name": "Pulmonary Fibrosis/Pneumonitis",
        "text": "History of idiopathic pulmonary fibrosis (IPF, including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan. (Note: History of radiation pneumonitis in the radiation field [fibrosis] is permitted.)",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_38",
        "name": "HBV Anti-viral Therapy",
        "text": "Current treatment with anti-viral therapy for HBV.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_39",
        "name": "Active Tuberculosis",
        "text": "Active tuberculosis.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_40",
        "name": "Live Vaccine",
        "text": "Receipt of a live, attenuated vaccine within 4 weeks prior to randomisation or anticipation that such a live, attenuated vaccine will be required during the study. Note: Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist®) within 28 days prior to randomisation, during treatment or within 5 months following the last dose of atezolizumab/placebo.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_41",
        "name": "Prior Checkpoint Inhibitors",
        "text": "Prior treatment with CD137 agonists, anti-PD-1, or anti-PD-L1 therapeutic antibody or immune checkpoint targeting agents.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_42",
        "name": "Immunostimulatory Agents",
        "text": "Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-2) within 4 weeks or five half-lives of the drug (whichever is longer) prior to randomisation.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_43",
        "name": "Immunosuppressive Medications",
        "text": "Treatment with systemic immunosuppressive medications (including but not limited to corticosteroids, cyclophosphamide, azathioprine, cyclosporine, methotrexate, thalidomide, and anti-tumour necrosis factor [TNF] agents) within 2 weeks prior to randomisation, or anticipated requirement for systemic immunosuppressive medications during the trial.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_44",
        "name": "Venous Access",
        "text": "Poor peripheral venous access",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_45",
        "name": "Substance Abuse",
        "text": "Illicit drug or alcohol abuse within 12 months prior to screening, in the investigator’s judgment",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_46",
        "name": "Investigator Judgment",
        "text": "Any other serious medical condition or abnormality in clinical laboratory tests that, in the investigator’s judgment, precludes the patient’s safe participation in and completion of the study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_47",
        "name": "Paclitaxel Hypersensitivity",
        "text": "History of hypersensitivity reactions to paclitaxel or other drugs formulated in the same solvent as paclitaxel (polyoxyethylated castor oil).",
        "instanceType": "EligibilityCriterionItem"
      }
    ],
    "eligibilityCriteria": [
      {
        "id": "ec_1",
        "identifier": "1",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_1",
        "instanceType": "EligibilityCriterion",
        "name": "Informed Consent",
        "nextId": "ec_2"
      },
      {
        "id": "ec_2",
        "identifier": "2",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_2",
        "instanceType": "EligibilityCriterion",
        "name": "Age Requirement",
        "previousId": "ec_1",
        "nextId": "ec_3"
      },
      {
        "id": "ec_3",
        "identifier": "3",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_3",
        "instanceType": "EligibilityCriterion",
        "name": "TNBC Diagnosis",
        "previousId": "ec_2",
        "nextId": "ec_4"
      },
      {
        "id": "ec_4",
        "identifier": "4",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_4",
        "instanceType": "EligibilityCriterion",
        "name": "Taxane Eligibility",
        "previousId": "ec_3",
        "nextId": "ec_5"
      },
      {
        "id": "ec_5",
        "identifier": "5",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_5",
        "instanceType": "EligibilityCriterion",
        "name": "Prior Therapy Status",
        "previousId": "ec_4",
        "nextId": "ec_6"
      },
      {
        "id": "ec_6",
        "identifier": "6",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_6",
        "instanceType": "EligibilityCriterion",
        "name": "Tumor Tissue Availability",
        "previousId": "ec_5",
        "nextId": "ec_7"
      },
      {
        "id": "ec_7",
        "identifier": "7",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_7",
        "instanceType": "EligibilityCriterion",
        "name": "ECOG Performance Status",
        "previousId": "ec_6",
        "nextId": "ec_8"
      },
      {
        "id": "ec_8",
        "identifier": "8",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_8",
        "instanceType": "EligibilityCriterion",
        "name": "Life Expectancy",
        "previousId": "ec_7",
        "nextId": "ec_9"
      },
      {
        "id": "ec_9",
        "identifier": "9",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_9",
        "instanceType": "EligibilityCriterion",
        "name": "Measurable Disease",
        "previousId": "ec_8",
        "nextId": "ec_10"
      },
      {
        "id": "ec_10",
        "identifier": "10",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_10",
        "instanceType": "EligibilityCriterion",
        "name": "Organ Function",
        "previousId": "ec_9",
        "nextId": "ec_11"
      },
      {
        "id": "ec_11",
        "identifier": "11",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_11",
        "instanceType": "EligibilityCriterion",
        "name": "HIV Status",
        "previousId": "ec_10",
        "nextId": "ec_12"
      },
      {
        "id": "ec_12",
        "identifier": "12",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_12",
        "instanceType": "EligibilityCriterion",
        "name": "Hepatitis B Status (HBsAg)",
        "previousId": "ec_11",
        "nextId": "ec_13"
      },
      {
        "id": "ec_13",
        "identifier": "13",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_13",
        "instanceType": "EligibilityCriterion",
        "name": "Hepatitis B Status (HBcAb)",
        "previousId": "ec_12",
        "nextId": "ec_14"
      },
      {
        "id": "ec_14",
        "identifier": "14",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_14",
        "instanceType": "EligibilityCriterion",
        "name": "Hepatitis C Status",
        "previousId": "ec_13",
        "nextId": "ec_15"
      },
      {
        "id": "ec_15",
        "identifier": "15",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_15",
        "instanceType": "EligibilityCriterion",
        "name": "Contraception (Women)",
        "previousId": "ec_14",
        "nextId": "ec_16"
      },
      {
        "id": "ec_16",
        "identifier": "16",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_16",
        "instanceType": "EligibilityCriterion",
        "name": "Pregnancy Test",
        "previousId": "ec_15",
        "nextId": "ec_17"
      },
      {
        "id": "ec_17",
        "identifier": "17",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_17",
        "instanceType": "EligibilityCriterion",
        "name": "Contraception (Men)",
        "previousId": "ec_16"
      },
      {
        "id": "ec_18",
        "identifier": "E1",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_18",
        "instanceType": "EligibilityCriterion",
        "name": "Spinal Cord Compression",
        "nextId": "ec_19"
      },
      {
        "id": "ec_19",
        "identifier": "E2",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_19",
        "instanceType": "EligibilityCriterion",
        "name": "CNS Disease",
        "previousId": "ec_18",
        "nextId": "ec_20"
      },
      {
        "id": "ec_20",
        "identifier": "E3",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_20",
        "instanceType": "EligibilityCriterion",
        "name": "Leptomeningeal Disease",
        "previousId": "ec_19",
        "nextId": "ec_21"
      },
      {
        "id": "ec_21",
        "identifier": "E4",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_21",
        "instanceType": "EligibilityCriterion",
        "name": "Effusions or Ascites",
        "previousId": "ec_20",
        "nextId": "ec_22"
      },
      {
        "id": "ec_22",
        "identifier": "E5",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_22",
        "instanceType": "EligibilityCriterion",
        "name": "Tumor-related Pain",
        "previousId": "ec_21",
        "nextId": "ec_23"
      },
      {
        "id": "ec_23",
        "identifier": "E6",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_23",
        "instanceType": "EligibilityCriterion",
        "name": "Hypercalcemia",
        "previousId": "ec_22",
        "nextId": "ec_24"
      },
      {
        "id": "ec_24",
        "identifier": "E7",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_24",
        "instanceType": "EligibilityCriterion",
        "name": "Other Malignancies",
        "previousId": "ec_23",
        "nextId": "ec_25"
      },
      {
        "id": "ec_25",
        "identifier": "E8",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_25",
        "instanceType": "EligibilityCriterion",
        "name": "Pregnancy/Lactation",
        "previousId": "ec_24",
        "nextId": "ec_26"
      },
      {
        "id": "ec_26",
        "identifier": "E9",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_26",
        "instanceType": "EligibilityCriterion",
        "name": "Uncontrolled Concomitant Disease",
        "previousId": "ec_25",
        "nextId": "ec_27"
      },
      {
        "id": "ec_27",
        "identifier": "E10",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_27",
        "instanceType": "EligibilityCriterion",
        "name": "Cardiovascular Disease",
        "previousId": "ec_26",
        "nextId": "ec_28"
      },
      {
        "id": "ec_28",
        "identifier": "E11",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_28",
        "instanceType": "EligibilityCriterion",
        "name": "Abnormal ECG",
        "previousId": "ec_27",
        "nextId": "ec_29"
      },
      {
        "id": "ec_29",
        "identifier": "E12",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_29",
        "instanceType": "EligibilityCriterion",
        "name": "Serious Infection",
        "previousId": "ec_28",
        "nextId": "ec_30"
      },
      {
        "id": "ec_30",
        "identifier": "E13",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_30",
        "instanceType": "EligibilityCriterion",
        "name": "Major Surgery",
        "previousId": "ec_29",
        "nextId": "ec_31"
      },
      {
        "id": "ec_31",
        "identifier": "E14",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_31",
        "instanceType": "EligibilityCriterion",
        "name": "Investigational Therapy",
        "previousId": "ec_30",
        "nextId": "ec_32"
      },
      {
        "id": "ec_32",
        "identifier": "E15",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_32",
        "instanceType": "EligibilityCriterion",
        "name": "Language/PRO Inability",
        "previousId": "ec_31",
        "nextId": "ec_33"
      },
      {
        "id": "ec_33",
        "identifier": "E16",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_33",
        "instanceType": "EligibilityCriterion",
        "name": "Antibody Hypersensitivity",
        "previousId": "ec_32",
        "nextId": "ec_34"
      },
      {
        "id": "ec_34",
        "identifier": "E17",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_34",
        "instanceType": "EligibilityCriterion",
        "name": "CHO Cell Hypersensitivity",
        "previousId": "ec_33",
        "nextId": "ec_35"
      },
      {
        "id": "ec_35",
        "identifier": "E18",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_35",
        "instanceType": "EligibilityCriterion",
        "name": "Autoimmune Disease",
        "previousId": "ec_34",
        "nextId": "ec_36"
      },
      {
        "id": "ec_36",
        "identifier": "E19",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_36",
        "instanceType": "EligibilityCriterion",
        "name": "Transplantation History",
        "previousId": "ec_35",
        "nextId": "ec_37"
      },
      {
        "id": "ec_37",
        "identifier": "E20",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_37",
        "instanceType": "EligibilityCriterion",
        "name": "Pulmonary Fibrosis/Pneumonitis",
        "previousId": "ec_36",
        "nextId": "ec_38"
      },
      {
        "id": "ec_38",
        "identifier": "E21",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_38",
        "instanceType": "EligibilityCriterion",
        "name": "HBV Anti-viral Therapy",
        "previousId": "ec_37",
        "nextId": "ec_39"
      },
      {
        "id": "ec_39",
        "identifier": "E22",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_39",
        "instanceType": "EligibilityCriterion",
        "name": "Active Tuberculosis",
        "previousId": "ec_38",
        "nextId": "ec_40"
      },
      {
        "id": "ec_40",
        "identifier": "E23",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_40",
        "instanceType": "EligibilityCriterion",
        "name": "Live Vaccine",
        "previousId": "ec_39",
        "nextId": "ec_41"
      },
      {
        "id": "ec_41",
        "identifier": "E24",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_41",
        "instanceType": "EligibilityCriterion",
        "name": "Prior Checkpoint Inhibitors",
        "previousId": "ec_40",
        "nextId": "ec_42"
      },
      {
        "id": "ec_42",
        "identifier": "E25",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_42",
        "instanceType": "EligibilityCriterion",
        "name": "Immunostimulatory Agents",
        "previousId": "ec_41",
        "nextId": "ec_43"
      },
      {
        "id": "ec_43",
        "identifier": "E26",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_43",
        "instanceType": "EligibilityCriterion",
        "name": "Immunosuppressive Medications",
        "previousId": "ec_42",
        "nextId": "ec_44"
      },
      {
        "id": "ec_44",
        "identifier": "E27",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_44",
        "instanceType": "EligibilityCriterion",
        "name": "Venous Access",
        "previousId": "ec_43",
        "nextId": "ec_45"
      },
      {
        "id": "ec_45",
        "identifier": "E28",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_45",
        "instanceType": "EligibilityCriterion",
        "name": "Substance Abuse",
        "previousId": "ec_44",
        "nextId": "ec_46"
      },
      {
        "id": "ec_46",
        "identifier": "E29",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_46",
        "instanceType": "EligibilityCriterion",
        "name": "Investigator Judgment",
        "previousId": "ec_45",
        "nextId": "ec_47"
      },
      {
        "id": "ec_47",
        "identifier": "E30",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_47",
        "instanceType": "EligibilityCriterion",
        "name": "Paclitaxel Hypersensitivity",
        "previousId": "ec_46"
      }
    ],
    "summary": {
      "inclusionCount": 17,
      "exclusionCount": 30,
      "totalCount": 47
    },
    "population": {
      "id": "pop_1",
      "name": "Study Population",
      "includesHealthySubjects": false,
      "criterionIds": [
        "ec_1",
        "ec_2",
        "ec_3",
        "ec_4",
        "ec_5",
        "ec_6",
        "ec_7",
        "ec_8",
        "ec_9",
        "ec_10",
        "ec_11",
        "ec_12",
        "ec_13",
        "ec_14",
        "ec_15",
        "ec_16",
        "ec_17",
        "ec_18",
        "ec_19",
        "ec_20",
        "ec_21",
        "ec_22",
        "ec_23",
        "ec_24",
        "ec_25",
        "ec_26",
        "ec_27",
        "ec_28",
        "ec_29",
        "ec_30",
        "ec_31",
        "ec_32",
        "ec_33",
        "ec_34",
        "ec_35",
        "ec_36",
        "ec_37",
        "ec_38",
        "ec_39",
        "ec_40",
        "ec_41",
        "ec_42",
        "ec_43",
        "ec_44",
        "ec_45",
        "ec_46",
        "ec_47"
      ],
      "instanceType": "StudyDesignPopulation",
      "description": "Target population defined by eligibility criteria"
    }
  },
  "rawResponse": {
    "eligibilityCriteria": [
      {
        "id": "ec_1",
        "name": "Informed Consent",
        "identifier": "1",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_1",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_2",
        "name": "Age Requirement",
        "identifier": "2",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_2",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_3",
        "name": "TNBC Diagnosis",
        "identifier": "3",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_3",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_4",
        "name": "Taxane Eligibility",
        "identifier": "4",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_4",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_5",
        "name": "Prior Therapy Status",
        "identifier": "5",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_5",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_6",
        "name": "Tumor Tissue Availability",
        "identifier": "6",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_6",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_7",
        "name": "ECOG Performance Status",
        "identifier": "7",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_7",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_8",
        "name": "Life Expectancy",
        "identifier": "8",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_8",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_9",
        "name": "Measurable Disease",
        "identifier": "9",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_9",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_10",
        "name": "Organ Function",
        "identifier": "10",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_10",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_11",
        "name": "HIV Status",
        "identifier": "11",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_11",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_12",
        "name": "Hepatitis B Status (HBsAg)",
        "identifier": "12",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_12",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_13",
        "name": "Hepatitis B Status (HBcAb)",
        "identifier": "13",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_13",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_14",
        "name": "Hepatitis C Status",
        "identifier": "14",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_14",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_15",
        "name": "Contraception (Women)",
        "identifier": "15",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_15",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_16",
        "name": "Pregnancy Test",
        "identifier": "16",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_16",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_17",
        "name": "Contraception (Men)",
        "identifier": "17",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_17",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_18",
        "name": "Spinal Cord Compression",
        "identifier": "E1",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_18",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_19",
        "name": "CNS Disease",
        "identifier": "E2",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_19",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_20",
        "name": "Leptomeningeal Disease",
        "identifier": "E3",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_20",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_21",
        "name": "Effusions or Ascites",
        "identifier": "E4",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_21",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_22",
        "name": "Tumor-related Pain",
        "identifier": "E5",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_22",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_23",
        "name": "Hypercalcemia",
        "identifier": "E6",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_23",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_24",
        "name": "Other Malignancies",
        "identifier": "E7",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_24",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_25",
        "name": "Pregnancy/Lactation",
        "identifier": "E8",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_25",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_26",
        "name": "Uncontrolled Concomitant Disease",
        "identifier": "E9",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_26",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_27",
        "name": "Cardiovascular Disease",
        "identifier": "E10",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_27",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_28",
        "name": "Abnormal ECG",
        "identifier": "E11",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_28",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_29",
        "name": "Serious Infection",
        "identifier": "E12",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_29",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_30",
        "name": "Major Surgery",
        "identifier": "E13",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_30",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_31",
        "name": "Investigational Therapy",
        "identifier": "E14",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_31",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_32",
        "name": "Language/PRO Inability",
        "identifier": "E15",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_32",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_33",
        "name": "Antibody Hypersensitivity",
        "identifier": "E16",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_33",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_34",
        "name": "CHO Cell Hypersensitivity",
        "identifier": "E17",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_34",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_35",
        "name": "Autoimmune Disease",
        "identifier": "E18",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_35",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_36",
        "name": "Transplantation History",
        "identifier": "E19",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_36",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_37",
        "name": "Pulmonary Fibrosis/Pneumonitis",
        "identifier": "E20",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_37",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_38",
        "name": "HBV Anti-viral Therapy",
        "identifier": "E21",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_38",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_39",
        "name": "Active Tuberculosis",
        "identifier": "E22",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_39",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_40",
        "name": "Live Vaccine",
        "identifier": "E23",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_40",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_41",
        "name": "Prior Checkpoint Inhibitors",
        "identifier": "E24",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_41",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_42",
        "name": "Immunostimulatory Agents",
        "identifier": "E25",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_42",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_43",
        "name": "Immunosuppressive Medications",
        "identifier": "E26",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_43",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_44",
        "name": "Venous Access",
        "identifier": "E27",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_44",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_45",
        "name": "Substance Abuse",
        "identifier": "E28",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_45",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_46",
        "name": "Investigator Judgment",
        "identifier": "E29",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_46",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_47",
        "name": "Paclitaxel Hypersensitivity",
        "identifier": "E30",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_47",
        "instanceType": "EligibilityCriterion"
      }
    ],
    "eligibilityCriterionItems": [
      {
        "id": "eci_1",
        "name": "Informed Consent",
        "text": "Signed Informed Consent Form",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_2",
        "name": "Age Requirement",
        "text": "Women or men aged ≥18 years",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_3",
        "name": "TNBC Diagnosis",
        "text": "Patients with locally advanced or metastatic, histologically documented TNBC (absence of human epidermal growth factor 2 [HER2], oestrogen receptor [ER], and progesterone receptor [PR] expression), not amenable to surgical therapy. a. HER2 negativity is defined as either of the following: IHC 0, IHC 1+ or IHC2+/in situ hybridisation (ISH)- as per American Society of Clinical Oncology (ASCO)- College of American Pathologists Guideline (CAP) guideline (ISH- is defined as a ratio of HER2 to CEP17 <2.0) (Wolff et al. 2018). b. ER and PR negativity are defined as <1% of cells expressing hormonal receptors via IHC analysis as per ASCO-CAP guideline (Hammond et al. 2010).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_4",
        "name": "Taxane Eligibility",
        "text": "Eligible for taxane monotherapy.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_5",
        "name": "Prior Therapy Status",
        "text": "No prior chemotherapy or targeted systemic therapy (including endocrine therapy) for inoperable locally advanced or metastatic TNBC. Prior radiation therapy for metastatic disease is permitted. There is no required minimum washout period for radiation therapy; however, patients should have recovered from the effects of radiation before randomisation. Previous chemotherapy for early breast cancer (eBC; neoadjuvant or adjuvant setting) is permitted if completed ≥12 months before randomisation. China Population only: Chinese traditional medicines with an approved indication for cancer treatment are permitted as long as the last administration occurred at least 2 weeks prior to randomisation.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_6",
        "name": "Tumor Tissue Availability",
        "text": "Availability of formalin-fixed paraffin-embedded (FFPE) tumour block (preferred) or at least 17 unstained slides, collected ≤3 months prior to randomisation, with an associated pathology report, if available. If a tumour sample taken within 3 months before randomisation is not available, and a tumour biopsy is not clinically feasible, the primary surgical resection sample or the most recent FFPE tumour biopsy sample may be used. Of these additional options, the most recent sample should be used. a. The tumour tissue should be of good quality based on total and viable tumour content and must be evaluated centrally for PD-L1 expression prior to enrolment. Patients whose tumour tissue is not evaluable for prospective central testing are not eligible. b. If multiple tumour specimens are submitted, patients may be eligible if at least one specimen is evaluable for PD-L1 testing, and the score measured in the most recent sample prior to enrolment will be used as the PD-L1 score for patient stratification. i. Acceptable samples include core needle biopsies for deep tumour tissue (more than one core if clinically feasible) or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions. ii. Fine needle aspiration, brushing, cell pellet from pleural effusion, bone metastases, and lavage samples are not acceptable. iii. Tumour tissue from bone metastases is not evaluable for PD-L1 expression and is therefore not acceptable.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_7",
        "name": "ECOG Performance Status",
        "text": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_8",
        "name": "Life Expectancy",
        "text": "Life expectancy ≥ 12 weeks",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_9",
        "name": "Measurable Disease",
        "text": "Measurable disease, as defined by RECIST v1.1. (Note: Previously irradiated lesions can be considered as measurable disease only if disease progression has been unequivocally documented at that site since radiation.)",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_10",
        "name": "Organ Function",
        "text": "Adequate haematologic and end-organ function, defined by the following laboratory results obtained within 2 weeks prior to the first study treatment (Cycle 1, Day 1): a. Absolute neutrophil count (ANC) ≥ 1500 cells/μL (without granulocyte colony stimulating factor [G-CSF] support within 2 weeks prior to Cycle 1, Day 1) b. Lymphocyte count ≥ 500/μL c. Platelet count ≥ 100,000/μL (without transfusion within 2 weeks prior to Cycle 1, Day 1) d. Haemoglobin ≥ 9.0 g/dL Patients may be transfused or receive erythropoietic treatment to meet this criterion. e. Aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase ≤ 2.5× the upper limit of normal (ULN), with the following exceptions: i. Patients with documented liver metastases: AST and ALT ≤ 5× ULN ii. Patients with documented liver or bone metastases: alkaline phosphatase ≤ 5× ULN f. Serum bilirubin ≤ 1.25× ULN Patients with known Gilbert’s disease who have serum bilirubin level ≤ 3× ULN may be enrolled. g. International Normalized Ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5× ULN This applies only to patients who are not receiving an anticoagulant medicinal product; patients receiving an anticoagulant medicinal product should be on a stable dose and have an INR which is not above the target therapeutic range. h. Calculated creatinine clearance (CrCl) ≥30 mL/min (Cockcroft-Gault).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_11",
        "name": "HIV Status",
        "text": "Negative human immunodeficiency virus (HIV) test at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_12",
        "name": "Hepatitis B Status (HBsAg)",
        "text": "Negative hepatitis B surface antigen (HBsAg) test at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_13",
        "name": "Hepatitis B Status (HBcAb)",
        "text": "Negative total hepatitis B core antibody (HBcAb) test at screening, or positive HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening. The HBV DNA test will be performed only for patients who have a positive HBcAb test.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_14",
        "name": "Hepatitis C Status",
        "text": "Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening. The HCV RNA test will be performed only for patients who have a positive HCV antibody test.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_15",
        "name": "Contraception (Women)",
        "text": "Women of child bearing potential must agree to either use a contraceptive method with a failure rate of ≤1% per year or to remain abstinent (refrain from heterosexual intercourse) during the treatment period and for at least 5 months after the last dose of atezolizumab/placebo, or for at least 6 months after the last dose of paclitaxel.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_16",
        "name": "Pregnancy Test",
        "text": "Women of child bearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study drug.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_17",
        "name": "Contraception (Men)",
        "text": "For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: a. With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of paclitaxel. Men must refrain from donating sperm during this same period. b. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_18",
        "name": "Spinal Cord Compression",
        "text": "Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for at least 2 weeks prior to randomisation",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_19",
        "name": "CNS Disease",
        "text": "Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases, provided all of the following criteria are met: a. Measurable disease outside the CNS b. Metastases are limited solely to cerebellar and supratentorial lesions (i.e., no metastases to midbrain, pons, medulla, or spinal cord) c. No ongoing requirement for corticosteroids as therapy for CNS disease (anticonvulsants at a stable dose are allowed) d. No stereotactic radiation within 7 days or whole-brain radiation within 14 days prior to randomisation e. No evidence of progression or haemorrhage after completion of CNS directed therapy Note: Patients with new asymptomatic CNS metastases detected at the screening scan must receive radiation therapy and/or surgery for CNS metastases. Following treatment, these patients may then be eligible if all other criteria above are met.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_20",
        "name": "Leptomeningeal Disease",
        "text": "Leptomeningeal disease",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_21",
        "name": "Effusions or Ascites",
        "text": "Uncontrolled pleural effusion, pericardial effusion, or ascites (Note: patients with indwelling catheters, such as PleurX® are allowed)",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_22",
        "name": "Tumor-related Pain",
        "text": "Uncontrolled tumour-related pain a. Patients requiring narcotic pain medication must be on a stable regimen at study entry. b. Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomisation. Patients should be recovered from the effects of radiation. There is no required minimum recovery period. c. Asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epidural metastasis that is not presently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to randomisation.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_23",
        "name": "Hypercalcemia",
        "text": "Uncontrolled hypercalcemia (>1.5 mmol/L [>6 mg/dL] ionized calcium or serum calcium [uncorrected for albumin] >3 mmol/L [>12 mg/dL] or corrected serum calcium > ULN) or clinically significant (symptomatic) hypercalcemia. Patients who are receiving bisphosphonate therapy specifically to prevent skeletal events and who do not have a history of clinically significant (symptomatic) hypercalcemia are eligible.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_24",
        "name": "Other Malignancies",
        "text": "Malignancies other than TNBC within 5 years prior to randomisation, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_25",
        "name": "Pregnancy/Lactation",
        "text": "Pregnant or lactating women, or intending to become pregnant during the study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_26",
        "name": "Uncontrolled Concomitant Disease",
        "text": "Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_27",
        "name": "Cardiovascular Disease",
        "text": "Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), myocardial infarction within 3 months prior to randomisation, unstable arrhythmias, or unstable angina. a. Patients with a known left ventricular ejection fraction (LVEF) < 40% will be excluded. b. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF < 50% must be on a stable medical regimen that is optimised in the opinion of the treating physician, in consultation with a cardiologist if appropriate.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_28",
        "name": "Abnormal ECG",
        "text": "Presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator’s opinion, including complete left bundle branch block, second- or third- degree heart block, evidence of prior myocardial infarction, or QT interval corrected using Fridericia’s formula (QTcF) > 470 ms demonstrated by at least two consecutive ECGs.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_29",
        "name": "Serious Infection",
        "text": "Serious infection requiring antibiotics within 2 weeks prior to randomisation, including but not limited to infections requiring hospitalisation or IV antibiotics, such as bacteraemia, or severe pneumonia.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_30",
        "name": "Major Surgery",
        "text": "Major surgical procedure within 4 weeks prior to randomisation or anticipation of the need for a major surgical procedure during the course of the study other than for diagnosis. Note: Placement of central venous access catheter(s) (e.g., port or similar) is not considered a major surgical procedure and is therefore permitted.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_31",
        "name": "Investigational Therapy",
        "text": "Treatment with investigational therapy within 30 days prior to initiation of study treatment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_32",
        "name": "Language/PRO Inability",
        "text": "Inability to understand the local language(s) for which the Patient Reported Outcome (PRO) questionnaires are available.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_33",
        "name": "Antibody Hypersensitivity",
        "text": "History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanised antibodies or fusion proteins.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_34",
        "name": "CHO Cell Hypersensitivity",
        "text": "Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary (CHO) cells or any component of the atezolizumab formulation.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_35",
        "name": "Autoimmune Disease",
        "text": "History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Guillain-Barré syndrome, multiple sclerosis (MS), vasculitis, or glomerulonephritis. (Note: Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study.)",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_36",
        "name": "Transplantation History",
        "text": "Prior allogeneic stem cell or solid organ transplantation",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_37",
        "name": "Pulmonary Fibrosis/Pneumonitis",
        "text": "History of idiopathic pulmonary fibrosis (IPF, including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan. (Note: History of radiation pneumonitis in the radiation field [fibrosis] is permitted.)",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_38",
        "name": "HBV Anti-viral Therapy",
        "text": "Current treatment with anti-viral therapy for HBV.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_39",
        "name": "Active Tuberculosis",
        "text": "Active tuberculosis.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_40",
        "name": "Live Vaccine",
        "text": "Receipt of a live, attenuated vaccine within 4 weeks prior to randomisation or anticipation that such a live, attenuated vaccine will be required during the study. Note: Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist®) within 28 days prior to randomisation, during treatment or within 5 months following the last dose of atezolizumab/placebo.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_41",
        "name": "Prior Checkpoint Inhibitors",
        "text": "Prior treatment with CD137 agonists, anti-PD-1, or anti-PD-L1 therapeutic antibody or immune checkpoint targeting agents.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_42",
        "name": "Immunostimulatory Agents",
        "text": "Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-2) within 4 weeks or five half-lives of the drug (whichever is longer) prior to randomisation.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_43",
        "name": "Immunosuppressive Medications",
        "text": "Treatment with systemic immunosuppressive medications (including but not limited to corticosteroids, cyclophosphamide, azathioprine, cyclosporine, methotrexate, thalidomide, and anti-tumour necrosis factor [TNF] agents) within 2 weeks prior to randomisation, or anticipated requirement for systemic immunosuppressive medications during the trial.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_44",
        "name": "Venous Access",
        "text": "Poor peripheral venous access",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_45",
        "name": "Substance Abuse",
        "text": "Illicit drug or alcohol abuse within 12 months prior to screening, in the investigator’s judgment",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_46",
        "name": "Investigator Judgment",
        "text": "Any other serious medical condition or abnormality in clinical laboratory tests that, in the investigator’s judgment, precludes the patient’s safe participation in and completion of the study.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_47",
        "name": "Paclitaxel Hypersensitivity",
        "text": "History of hypersensitivity reactions to paclitaxel or other drugs formulated in the same solvent as paclitaxel (polyoxyethylated castor oil).",
        "instanceType": "EligibilityCriterionItem"
      }
    ],
    "population": {
      "id": "pop_1",
      "name": "Study Population",
      "includesHealthySubjects": false,
      "plannedEnrollmentNumber": {
        "maxValue": 730,
        "instanceType": "Range"
      },
      "plannedMinimumAge": "P18Y",
      "plannedMaximumAge": null,
      "plannedSex": [
        {
          "code": "Male",
          "codeSystem": "http://www.cdisc.org/USDM/sex",
          "decode": "Male"
        },
        {
          "code": "Female",
          "codeSystem": "http://www.cdisc.org/USDM/sex",
          "decode": "Female"
        }
      ],
      "criterionIds": [
        "ec_1",
        "ec_2",
        "ec_3",
        "ec_4",
        "ec_5",
        "ec_6",
        "ec_7",
        "ec_8",
        "ec_9",
        "ec_10",
        "ec_11",
        "ec_12",
        "ec_13",
        "ec_14",
        "ec_15",
        "ec_16",
        "ec_17",
        "ec_18",
        "ec_19",
        "ec_20",
        "ec_21",
        "ec_22",
        "ec_23",
        "ec_24",
        "ec_25",
        "ec_26",
        "ec_27",
        "ec_28",
        "ec_29",
        "ec_30",
        "ec_31",
        "ec_32",
        "ec_33",
        "ec_34",
        "ec_35",
        "ec_36",
        "ec_37",
        "ec_38",
        "ec_39",
        "ec_40",
        "ec_41",
        "ec_42",
        "ec_43",
        "ec_44",
        "ec_45",
        "ec_46",
        "ec_47"
      ],
      "instanceType": "StudyDesignPopulation"
    }
  }
}